Compare Fabrinet (FN) vs Pfizer Inc (PFE) Price & Performance

Fabrinet (FN) trades at $493.25, down 0.95% amid mixed technical signals with bullish moving averages but overbought RSI readings. The company demonstrates strong fundamental performance with 45% Q4 revenue growth and consistent earnings beats, driven by surging AI data center demand. Analyst consensus remains strongly bullish with a $769.50 price target representing 56% upside potential, though the stock faces near-term pressure from high capital expenditures.

Fabrinet's AI infrastructure positioning and capacity expansion support long-term growth prospects, but investors should monitor customer concentration risks and margin pressures. The stock's premium valuation (P/E 37.34) requires continued execution on growth targets to justify current levels amid competitive optical component market dynamics.

Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.

The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.